261.39
前日終値:
$259.45
開ける:
$259.53
24時間の取引高:
597.37K
Relative Volume:
0.78
時価総額:
$21.71B
収益:
$12.71B
当期純損益:
$435.50M
株価収益率:
50.76
EPS:
5.15
ネットキャッシュフロー:
$843.20M
1週間 パフォーマンス:
+0.55%
1か月 パフォーマンス:
+4.76%
6か月 パフォーマンス:
+15.50%
1年 パフォーマンス:
+26.58%
Labcorp Holdings Inc Stock (LH) Company Profile
LH を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
LH
Labcorp Holdings Inc
|
261.39 | 21.71B | 12.71B | 435.50M | 843.20M | 5.15 |
![]()
TMO
Thermo Fisher Scientific Inc
|
392.56 | 156.49B | 42.90B | 6.52B | 6.72B | 17.05 |
![]()
DHR
Danaher Corp
|
194.44 | 145.01B | 23.82B | 3.77B | 4.90B | 5.15 |
![]()
IDXX
Idexx Laboratories Inc
|
519.85 | 42.30B | 3.93B | 894.97M | 837.70M | 10.82 |
![]()
A
Agilent Technologies Inc
|
115.52 | 34.24B | 6.63B | 1.17B | 1.19B | 4.05 |
![]()
IQV
Iqvia Holdings Inc
|
154.61 | 27.64B | 15.50B | 1.33B | 2.16B | 7.34 |
Labcorp Holdings Inc Stock (LH) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-04-02 | 開始されました | Redburn Atlantic | Buy |
2025-03-04 | アップグレード | Citigroup | Neutral → Buy |
2025-01-07 | アップグレード | Evercore ISI | In-line → Outperform |
2024-12-10 | 再開されました | Jefferies | Buy |
2024-10-30 | アップグレード | HSBC Securities | Hold → Buy |
2024-10-01 | 開始されました | Piper Sandler | Neutral |
2024-03-25 | アップグレード | Argus | Hold → Buy |
2024-02-26 | 開始されました | Leerink Partners | Outperform |
2024-02-09 | 開始されました | Evercore ISI | In-line |
2024-01-03 | 開始されました | Barclays | Equal Weight |
2023-09-06 | 開始されました | HSBC Securities | Hold |
2022-12-12 | ダウングレード | Citigroup | Buy → Neutral |
2022-09-19 | ダウングレード | Argus | Buy → Hold |
2022-08-22 | 再開されました | Morgan Stanley | Overweight |
2022-01-28 | ダウングレード | Deutsche Bank | Buy → Hold |
2021-01-11 | アップグレード | Argus | Hold → Buy |
2021-01-11 | ダウングレード | Wolfe Research | Peer Perform → Underperform |
2021-01-08 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
2020-07-14 | アップグレード | BofA Securities | Neutral → Buy |
2020-07-13 | アップグレード | Wolfe Research | Peer Perform → Outperform |
2020-06-02 | 再開されました | Deutsche Bank | Buy |
2020-05-15 | アップグレード | Mizuho | Neutral → Buy |
2020-04-29 | ダウングレード | KeyBanc Capital Markets | Overweight → Sector Weight |
2020-04-27 | アップグレード | Citigroup | Neutral → Buy |
2020-04-27 | アップグレード | Wolfe Research | Underperform → Peer Perform |
2020-01-08 | 開始されました | Wells Fargo | Overweight |
2019-07-16 | アップグレード | BofA/Merrill | Underperform → Neutral |
2019-06-21 | アップグレード | Deutsche Bank | Hold → Buy |
2019-04-02 | アップグレード | Jefferies | Hold → Buy |
2019-01-17 | 開始されました | UBS | Buy |
2019-01-03 | ダウングレード | BofA/Merrill | Neutral → Underperform |
2018-12-03 | ダウングレード | Craig Hallum | Buy → Hold |
2018-10-30 | ダウングレード | Argus | Buy → Hold |
2018-10-25 | ダウングレード | Canaccord Genuity | Buy → Hold |
2018-10-19 | 再開されました | BofA/Merrill | Buy |
2018-06-07 | アップグレード | KeyBanc Capital Mkts | Sector Weight → Overweight |
2018-05-01 | アップグレード | Robert W. Baird | Neutral → Outperform |
2018-03-23 | 開始されました | Argus | Buy |
すべてを表示
Labcorp Holdings Inc (LH) 最新ニュース
Labcorp Stock Climbs 25.6% This Year: What's Driving the Surge? - Nasdaq
Labcorp Launches Labcorp Whole Health Solutions to Support Holistic Care - marketscreener.com
Labcorp Revolutionizes Healthcare Testing with New 1000+ Biomarker Platform for Holistic Medicine - Stock Titan
Baird Adjusts Price Target on Labcorp Holdings to $290 From $268, Maintains Outperform Rating - MarketScreener
Morgan Stanley Hikes Labcorp (LH) Holdings Price Target to $283 Affirms ‘Overweight’ Rating - Yahoo Finance
FTRE INVESTOR DEADLINE: Robbins Geller Rudman & Dowd Announces that Fortrea Holdings Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - The Malaysian Reserve
Pomerantz Law Firm Announces the Filing of a Class Action Against Fortrea Holdings, Inc. and Certain Officers – FTRE - FinancialContent
Kaplan Fox Reminds Fortrea Holdings Inc. (FTRE) Investors of a Securities Class Action Deadline on August 1, 2025 - FinancialContent
Class Standing Issues Still Murky After Justices Punt LabCorp - Law360
Labcorp (LH) Gains Exclusive 3D Liver Models from Predictive Onc - GuruFocus
Labcorp director Kerrii Anderson sells shares worth $130,000 By Investing.com - Investing.com Canada
Labcorp director Kerrii Anderson sells shares worth $130,000 - Investing.com Australia
Predictive Oncology Develops 3D Liver Toxicity Models for Labcorp - marketscreener.com
Predictive Oncology Inc. Develops Functional 3D Organoid Models Exclusively for Labcorp - MarketScreener
Kaplan Fox Encourages Investors of Fortrea Holdings Inc. (FTRE) to Contact the Firm Before Lead Plaintiff Deadline on August 1, 2025 - The Globe and Mail
Investing in Labcorp Holdings (NYSE:LH) five years ago would have delivered you a 85% gain - simplywall.st
Predictive Oncology Inc. Develops Exclusive 3D Organoid Models for Labcorp to Enhance Drug Discovery and Safety Evaluation - Nasdaq
Predictive Oncology Develops Functional 3D Organoid Models Exclusively for Labcorp - Yahoo Finance
Labcorp Hldgs (LH) Price Target Raised by Morgan Stanley | LH St - GuruFocus
Kirby McInerney LLP Reminds Fortrea Holdings Inc. (FTRE) Investors of Class Action Filing and Encourages Investors to Contact the Firm - FinancialContent
Kaplan Fox Alerts Investors to a Securities Class Action Against Fortrea Holdings Inc. (FTRE)Deadline is August 1, 2025 - The Globe and Mail
Labcorp v. Davis Challenge Regarding Uninjured Class Members Dismissed as Improvidently Granted - Wilson Sonsini
What 8 Analyst Ratings Have To Say About Labcorp Hldgs - Benzinga
Just One Day Away – Register Now for HMG Strategy’s 9th Annual New York CISO & Technology Leadership Summit on June 12 - GlobeNewswire Inc.
Labcorp Hldgs (LH) Price Target Raised by Morgan Stanley | LH Stock News - GuruFocus
Analyst Boosts Price Target for Labcorp (LH) Amid Positive Growt - GuruFocus
Morgan Stanley Raises Price Target on Labcorp Holdings to $283 From $270 - marketscreener.com
LabCorp stock hits 52-week high at $258.7 amid robust growth By Investing.com - Investing.com South Africa
Justice Kavanaugh Signals One Conservative Vote in Labcorp Toward Imposing a Pre-Certification Standing Requirement Under FRCP 23 - The National Law Review
LabCorp stock hits 52-week high at $258.7 amid robust growth - Investing.com India
InStride Redefines Workforce Development Through Strategic Expansion - GlobeNewswire Inc.
FTRE INVESTOR ALERT: Fortrea Holdings Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - The Malaysian Reserve
SCOTUS Declines to Decide Fate of Classes with Uninjured Members: 8-1 Decision in LabCorp Leaves Unresolved Whether Rule 23 Allows Certification for a Class Containing Members Who Lack Standing - The National Law Review
SCOTUS DECLINES TO DECIDE FATE OF CLASSES WITH UNINJURED MEMBERS: 8-1 Decision In LabCorp Leaves Unresolved Whether Rule 23 Allows Certification For A Class Containing Members Who Lack Standing - TCPAWorld
Supreme Court backs off class-action case involving Labcorp, leaving legal questions unresolved - The Business Journals
Insider Sell: Brian Caveney Sells 2,000 Shares of Labcorp Holdin - GuruFocus
Should You Continue to Hold Labcorp Stock in Your Portfolio? - MSN
Labcorp EVP Brian Caveney sells $494,000 in common stock By Investing.com - Investing.com Canada
Labcorp EVP Brian Caveney sells $494,000 in common stock - Investing.com Australia
FTRE BREAKING NEWS: Fortrea Holdings Inc. Stock Plummets 25% Triggering Shareholder Class Action – Contact BFA Law if You Lost Money (NASDAQ:FTRE) - Business Wire
High Court Drops Class Cert. Clarification Bid - Law360
Labcorp Holdings Insider Sold Shares Worth $494,000, According to a Recent SEC Filing - marketscreener.com
Fortrea Faces Investor Suit Over Post-Labcorp Financial Woes - Law360
FTRE INVESTOR ALERT: Fortrea Holdings Inc. Investors with Substantial Losses Have Opportunity to Lead the Fortrea Class Action Lawsuit - The Malaysian Reserve
FTRE Stockholder Alert: Robbins LLP Informs Investors of the Fortrea Holdings, Inc. Class Action Lawsuit - Morningstar
Labcorp Adds New Tests for Solid Tumors, Hematologic Malignancies - marketscreener.com
Labcorp Expands Oncology Portfolio to Improve Patient Care, Advance Cancer Research - marketscreener.com
Labcorp Expands Oncology Portfolio to Improve Patient Care and A - GuruFocus
Labcorp (LH) Expands Precision Oncology Portfolio with New Offerings | LH Stock News - GuruFocus
Labcorp Expands Oncology Portfolio to Improve Patient Care and Advance Cancer Research - Financial Times
Labcorp Revolutionizes Cancer Care: New Test Portfolio Promises Faster Treatment Decisions - Stock Titan
Labcorp Holdings Inc (LH) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):